Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Sims

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Nature Reviews. Immunology|September 4, 2012
Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trialChristopher Horvath, Laura Andrews, Andreas Baumann, et al.
Regulatory Toxicology and Pharmacology : RTP|November 22, 2011
The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of non-human primatesKathryn L Chapman, Laura Andrews, Jeffrey J Bajramovic, et al.
Toxicologic Pathology|August 5, 2015
PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical DevelopmentInge A Ivens, William Achanzar, Andreas Baumann, et al.
Journal of Immunotoxicology|October 30, 2008
Development of the ICH guidelines for immunotoxicology evaluation of pharmaceuticals using a survey of industry practicesJames L Weaver, Naohisa Tsutsui, Shigeru Hisada, et al.
Molecular Therapy. Methods & Clinical Development|October 21, 2024
A novel AAV9-dual microRNA-vector targeting <i>GRIK2</i> in the hippocampus as a treatment for mesial temporal lobe epilepsyStéphane J Baudouin, April R Giles, Nick Pearson, et al.
Science Translational Medicine|October 20, 2021
Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell-mediated antitumor immune responseAude De Gassart, Kieu-Suong Le, Patrick Brune, et al.
Nature Reviews. Drug Discovery|March 29, 2013
Challenges and approaches for the development of safer immunomodulatory biologicsJean G Sathish, Swaminathan Sethu, Marie-Christine Bielsky, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Nature Reviews. Immunology|September 4, 2012
Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trialChristopher Horvath, Laura Andrews, Andreas Baumann, et al.
Regulatory Toxicology and Pharmacology : RTP|November 22, 2011
The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of non-human primatesKathryn L Chapman, Laura Andrews, Jeffrey J Bajramovic, et al.
Toxicologic Pathology|August 5, 2015
PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical DevelopmentInge A Ivens, William Achanzar, Andreas Baumann, et al.
Journal of Immunotoxicology|October 30, 2008
Development of the ICH guidelines for immunotoxicology evaluation of pharmaceuticals using a survey of industry practicesJames L Weaver, Naohisa Tsutsui, Shigeru Hisada, et al.
Molecular Therapy. Methods & Clinical Development|October 21, 2024
A novel AAV9-dual microRNA-vector targeting <i>GRIK2</i> in the hippocampus as a treatment for mesial temporal lobe epilepsyStéphane J Baudouin, April R Giles, Nick Pearson, et al.
Science Translational Medicine|October 20, 2021
Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell-mediated antitumor immune responseAude De Gassart, Kieu-Suong Le, Patrick Brune, et al.
Nature Reviews. Drug Discovery|March 29, 2013
Challenges and approaches for the development of safer immunomodulatory biologicsJean G Sathish, Swaminathan Sethu, Marie-Christine Bielsky, et al.
Pageof 6